Top

Cancer Causes & Control

Published in:

01-06-2013 | Original paper

The effect of multiple primary rules on population-based cancer survival

Authors: Hannah K. Weir, Christopher J. Johnson, Trevor D. Thompson

Published in: Cancer Causes & Control | Issue 6/2013

Abstract

Purpose

Different rules for registering multiple primary (MP) cancers are used by cancer registries throughout the world, making international data comparisons difficult. This study evaluates the effect of Surveillance, Epidemiology, and End Results (SEER) and International Association of Cancer Registries (IACR) MP rules on population-based cancer survival estimates.

Methods

Data from five US states and six metropolitan area cancer registries participating in the SEER Program were used to estimate age-standardized relative survival (RS%) for first cancers-only and all first cancers matching the selection criteria according to SEER and IACR MP rules for all cancer sites combined and for the top 25 cancer site groups among men and women.

Results

During 1995–2008, the percentage of MP cancers (all sites, both sexes) increased 25.4 % by using SEER rules (from 14.6 to 18.4 %) and 20.1 % by using IACR rules (from 13.2 to 15.8 %). More MP cancers were registered among females than among males, and SEER rules registered more MP cancers than IACR rules (15.8 vs. 14.4 % among males; 17.2 vs. 14.5 % among females). The top 3 cancer sites with the largest differences were melanoma (5.8 %), urinary bladder (3.5 %), and kidney and renal pelvis (2.9 %) among males, and breast (5.9 %), melanoma (3.9 %), and urinary bladder (3.4 %) among females. Five-year survival estimates (all sites combined) restricted to first primary cancers-only were higher than estimates by using first site-specific primaries (SEER or IACR rules), and for 11 of 21 sites among males and 11 of 23 sites among females. SEER estimates are comparable to IACR estimates for all site-specific cancers and marginally higher for all sites combined among females (RS 62.28 vs. 61.96 %).

Conclusion

Survival after diagnosis has improved for many leading cancers. However, cancer patients remain at risk of subsequent cancers. Survival estimates based on first cancers-only exclude a large and increasing number of MP cancers. To produce clinically and epidemiologically relevant and less biased cancer survival estimates, data on all cancers should be included in the analysis. The multiple primary rules (SEER or IACR) used to identify primary cancers do not affect survival estimates if all first cancers matching the selection criteria are used to produce site-specific survival estimates.

Brewster DH, Coebergh JW, Storm HH (2005) Population-based cancer registries: the invisible key to cancer control. Lancet Oncol 6(4):193–195PubMedCrossRef

Rachet B, Maringe C, Nur U et al (2009) Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol 10(4):351–369PubMedCrossRef

Howlader NNA, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2012) SEER cancer statistics review, 1975–2009 (Vintage 2009 Populations). National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, Apr 2012

U.S. Cancer Statistics Working Group (2012) United States cancer statistics: 1999–2008 incidence and mortality web-based report. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, Atlanta. Available at: www.cdc.gov/uscs

Canadian Cancer Society’s Steering Committee on Cancer Statistics (2012) Canadian cancer statistics 2012. Canadian Cancer Society, Toronto, ON

Copeland G, Lake A, Firth R, Wohler B, Wu XC, Stroup A, Russell C, Kimberley B, Niu X, Schymura M, Hofferkamp J, Kohler B (eds) (2011) Cancer in North America: 2004–2008. Volume one: combined cancer incidence for the United States and Canada. North American Association of Central Cancer Registries, Inc., Springfield, IL

Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (eds) (2007) Cancer incidence in five continents, vol IX. IARC Scientific Publications No. 160, Lyon

Berrino F, Verdecchia A, Lutz JM et al (2009) Comparative cancer survival information in Europe. Eur J Cancer 45(6):901–908PubMedCrossRef

Coleman MP, Quaresma M, Berrino F et al (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9(8):730–756PubMedCrossRef

10.

Coleman MP, Forman D, Bryant H et al (2011) Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 377(9760):127–138PubMedCrossRef

11.

Hankey BF, Ries LA, Edwards BK (1999) The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomark Prev 8(12):1117–1121

12.

Lourie WI (ed) (1976) The 1976 SEER code manual. The National Cancer Institute Biometry Branch, Bethesda, MD

13.

SEER Program Code Manual. NIH Publication No. 79-199, Bethesda, MD, June 1, 1979

14.

SEER code manual. National Cancer Institute, Bethesda, MD. Revised May 1988

15.

SEER code manual. National Cancer Institute, Bethesda, MD. Revised June 1992

16.

SEER code manual, 3rd edn. National Cancer Institute, Bethesda, MD. Revised Jan 1998

17.

Johnson CH, Peace S, Adamo P, Fritz A, Percy-Laurry A, Edwards BK (2007) The 2007 multiple primary and histology coding rules. National Cancer Institute, Surveillance, Epidemiology and End Results Program, Bethesda, MD

18.

Thornton M (ed) Standards for cancer registries volume II: data standards and data dictionary, 16th edn, record layout version 12.2

19.

Working Group Report (2005) International rules for multiple primary cancers (ICD-0 third edition). Eur J Cancer Prev 14(4):307–308CrossRef

20.

Ferlay J, Burkhard C, Whelan S, Parkin DM (2005) Check and conversion programs for cancer registries. IACR/IACR tools for cancer registries. IACR Technical Report No. 42, Lyon

21.

Ries LAG, Young JL, Keel GE et al (eds) (2007) SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988–2001, patient and tumor characteristics. NIH Pub. No. 07-6215, National Cancer Institute, Bethesda, MD

22.

Brenner H, Hakulinen T (2007) Patients with previous cancer should not be excluded in international comparative cancer survival studies. Int J Cancer 121(10):2274–2278PubMedCrossRef

23.

Rosso S, De Angelis R, Ciccolallo L et al (2009) Multiple tumours in survival estimates. Eur J Cancer 45(6):1080–1094PubMedCrossRef

24.

Ellison LF (2010) Measuring the effect of including multiple cancers in survival analyses using data from the Canadian Cancer Registry. Cancer Epidemiol 34(5):550–555PubMedCrossRef

25.

Brenner H, Gondos A, Arndt V (2007) Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J Clin Oncol 25(22):3274–3280PubMedCrossRef

26.

Lifetime Mobility in the United States: 2010. U.S. Census Bureau ACS, 2010 Puerto Rico Community Survey

27.

Sharpe A, Arsenault JF, Ershov D (2007) The impact of interprovincial migration on aggregate output and labour productivity in Canada, 1987–2006. International Productivity Monitor, Centre for the Study of Living Standards, vol 15, pp 25–40, Fall

28.

Fritz A, Percy C, Jack A (2000) International classification of diseases of oncology. World Health Organization, Geneva

29.

SEER Site Recode ICD-O-3 (1/27/2003) Definition. Available at: http://seer.cancer.gov/siterecode/icdo3_d01272003. Accessed June 28

30.

Ederer F, Axtell LM, Cutler SJ (1961) The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 6:101–121PubMed

31.

Corazziari I, Quinn M, Capocaccia R (2004) Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40(15):2307–2316PubMedCrossRef

32.

33.

Dckman PW, Adami HO (2006) Interpreting trends in cancer patient survival. J Intern Med 260:103–117CrossRef

34.

Baili P, Micheli A, De Angelis R, Weir HK, Francisci S, Santaquilani M, Hakulinen T, Quaresmas M, Coleman MP, CONCORD Working Group (2008) Life tables for world-wide comparison of relative survival for cancer (CONCORD study). Tumori 94(5):658–668PubMed

Title: The effect of multiple primary rules on population-based cancer survival
Authors: Hannah K. Weir
Christopher J. Johnson
Trevor D. Thompson
Publication date: 01-06-2013
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 6/2013
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-013-0203-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2013

Disentangling the effects of race/ethnicity and socioeconomic status of neighborhood in cancer stage distribution in New York City

Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study

Consumption of fruit, vegetables, and other food groups and the risk of nasopharyngeal carcinoma

Analgesic use in relation to sex hormone and prolactin concentrations in premenopausal women

Associations between urinary soy isoflavonoids and two inflammatory markers in adults in the United States in 2005–2008

Risk of prostate cancer death in long-term users of warfarin: a population-based case–control study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer